Mergers & Acquisitions - Licensing

Filter

Current filters:

Licensing

Popular Filters

82 to 106 of 1740 results

Celladon signs option agreement with Servier

24-02-2014

USA-based biotech firm Celladon has entered into an option agreement with French independent drugmaker…

BiotechnologyCelladonDiabetesLicensingServier

Dilafor partners with Lee’s Pharmaceutical for tafoxiparin

24-02-2014

Sweden-based Dilafor AB, a Karolinska Development portfolio company, and Lee’s Pharmaceutical Holdings,…

Asia-PacificChinaDilafor ABKarolinska DevelopmentLee's PharmaceuticalLicensingPharmaceuticalReproductivetafoxiparinWomen's Health

ThromboGenics explores “strategic options” for the company

ThromboGenics explores “strategic options” for the company

24-02-2014

Belgian biotech firm ThromboGenics revealed this morning that it has retained financial advisor Morgan…

AlconBiotechnologyLicensingMergers & AcquisitionsNovartisOphthalmicsThromboGenics

Indian drugmakers readying for next “Patent cliff”

24-02-2014

The strategic drug reviews, as well as mergers and acquisitions – such as Actavis buying out Forest…

Asia-PacificGenericsIndiaMergers & AcquisitionsPatentsPharmaceuticalRegulation

Nuevolution announces license agreement with Merck

Nuevolution announces license agreement with Merck

21-02-2014

Denmark-based Nuevolution has entered an exclusive license agreement with a subsidiary of US pharma giant…

LicensingMerck & CoNuevolutionPharmaceuticalUK

Fitch affirms Actavis at “BBB-” on Forest Labs acquisition; outlook Stable

20-02-2014

Fitch Ratings has affirmed the ratings of generic drugs major Actavis and subsidiaries at “BBB-”…

ActavisFinancialForest LaboratoriesMergers & AcquisitionsPharmaceutical

Nestle takes full control of Galderma Pharma

19-02-2014

The boards of Switzerland-based Nestle, the world’s largest food company, and French cosmetics firm…

DermatologicalsGaldermaMergers & AcquisitionsNestlePharmaceutical

Actavis confirms plan to acquire Forest Labs for about $25 billion

Actavis confirms plan to acquire Forest Labs for about $25 billion

18-02-2014

After a morning of speculation and rumors, generics drug major Actavis today confirmed that it has reached…

ActavisForest LaboratoriesGenericsMergers & AcquisitionsPharmaceutical

ProductLife Group expands German operations with acquisition

18-02-2014

UK life sciences outsourcing and consulting services specialist ProductLife Group (PLG) has announced…

Kohne PharmaMergers & AcquisitionsPharmaceuticalProductLife Group

Servier and Cellectis collaborate on leukemia and solid tumors candidates

Servier and Cellectis collaborate on leukemia and solid tumors candidates

18-02-2014

Allogeneic CAR T-cell therapies specialist Cellectis has signed a strategic collaboration agreement with…

CellectisLicensingOncologyPharmaceuticalResearchServierUCART19

Prothelia and Alexion partner with University of Nevada for ultra-rare neuromuscular disorder

Prothelia and Alexion partner with University of Nevada for ultra-rare neuromuscular disorder

17-02-2014

Privately-held USA-based Prothelia and the University of Nevada, Reno, have entered into strategic agreements…

Alexion PharmaceuticalsMergers & AcquisitionsPharmaceuticalProtheliaRare diseasesResearch

X-Chem licenses drug discovery program to Bayer

X-Chem licenses drug discovery program to Bayer

17-02-2014

X-Chem Inc, a privately held US biotechnology company focused on applying its innovative drug discovery…

BayerBiotechnologyLicensingOncologyX-Chem

Oxford BioMedica concludes novel ocular license deal with Sanofi

Oxford BioMedica concludes novel ocular license deal with Sanofi

17-02-2014

UK-based Oxford BioMedica has concluded the terms of the development and commercialization license agreement…

BiotechnologyLicensingOphthalmicsOxford BioMedicaUK

Novartis to acquire CoStim, expanding cancer immunotherapy research program

Novartis to acquire CoStim, expanding cancer immunotherapy research program

17-02-2014

Swiss drug major Novartis said this morning that it is broadening its cancer immunotherapy research program…

BiotechnologyCoStim PharmaceuticalsMergers & AcquisitionsNovartisOncology

AVEO and Astellas finally terminate tivozanib collaboration

14-02-2014

US biotech firm AVEO Oncology and Japanese drug major Astellas Pharma are to end their worldwide collaboration…

Astellas PharmaAVEO OncologyBiotechnologyLicensingOncologytivozanib

Daiichi Sankyo and UMN Pharma collaborate over norovirus vaccine

Daiichi Sankyo and UMN Pharma collaborate over norovirus vaccine

14-02-2014

Japanese drug companies Daiichi Sankyo and UMN Pharma have signed a collaborative research agreement…

Daiichi SankyoJapanLicensingPharmaceuticalResearchVaccines

NicOx appoints financial partner to assess Duchenne Muscular Dystrophy treatment

14-02-2014

French biotechnology firm NicOx (Euronext Paris: COX) has granted an undisclosed financial partner an…

BiotechnologyFranceGeneticsLicensingnaproxcinodNicOx

Another milestone for GenVec in hearing and balance collaboration

13-02-2014

US biotech firm GenVec says it has achieved the third milestone in its collaboration with Swiss drug…

BiotechnologyCGF166FinancialGenVecLicensingNeurologicalNovartis

Infectex acquires exclusive rights to Qurient's TB drug Q203

13-02-2014

Russian and Korean biotech companies Infectex and Qurient have entered a license agreement granting Infectex…

Antibiotics and Infectious diseasesEastern EuropeInfectexLicensingPharmaceuticalQ203QurientRussia

Retrophin to acquire Manchester Pharma in $62.5 million deal

Retrophin to acquire Manchester Pharma in $62.5 million deal

13-02-2014

USA-based Retrophin has signed an agreement to acquire Manchester Pharmaceuticals, a privately-held specialty…

Cardio-vascularChenodalManchester PharmaceuticalsMergers & AcquisitionsPharmaceuticalRare diseasesRetrophinVecamyl

UCB links with UK’s MRC Technology for a fibrosis program

UCB links with UK’s MRC Technology for a fibrosis program

13-02-2014

Belgium’s leading drugmaker UCB and UK’s MRC Technology have entered an exclusive license agreement,…

LicensingPharmaceuticalResearchUCB

Aurigene and Pierre Fabre announce licensing agreement for novel immunotherapy

Aurigene and Pierre Fabre announce licensing agreement for novel immunotherapy

13-02-2014

Privately-owned Pierre Fabre and Aurigene, a leading Indian biotech company, have entered into an agreement…

Aurigene DiscoveryBiotechnologyFranceIndiaLicensingOncologyPierre Fabre

La Jolla Pharma gains hepcidin agonists rights from INSERM

12-02-2014

San Diego, USA-based drug developer La Jolla Pharmaceutical has entered into an exclusive worldwide license…

HematologyLa Jolla PharmaceuticalLicensingPharmaceuticalResearch

Mallinckrodt to buy Cadence Pharma for around $1.3 billion

12-02-2014

Ireland-headquartered specialty drugmaker Mallinckrodt, spun off by Covidien last year, has entered into…

Cadence PharmaceuticalsMallinckrodtMergers & AcquisitionsOfirmevPharmaceutical

82 to 106 of 1740 results

Back to top